Tirzepatide tied to weight loss and metabolic gains in partial lipodystrophy study
The findings suggest a possible role for tirzepatide in a rare fat-storage disorder, but the study's design cannot prove the drug caused the improvements.
A single-center retrospective study published in the Journal of Clinical Endocrinology and Metabolism reports that tirzepatide was associated with weight loss and improvements in metabolic measures in people with partial lipodystrophy, a rare fat-storage disorder [1]. The study included all 40 patients with partial lipodystrophy treated with tirzepatide at one center between January 2022 and September 2025 [1].
Over a median of 9.5 months, median body weight fell from 91.0 kg to 82.8 kg, a difference of 8.2 kg [1]. The study also reported significant reductions in glycemic control measures, serum triglycerides, and daily insulin requirement [1]. The patients represented several genetic subtypes of partial lipodystrophy [1]. The study did not report the exact size of those reductions, the specific glycemic control measures used, or the dose of tirzepatide given [1].
The study is retrospective, meaning it looked back at medical records, and it has no control group [1]. Without a control group, the results cannot show that tirzepatide caused the improvements; other factors could have played a role [1]. The single-center design also means the findings may not apply to all patients with partial lipodystrophy [1]. The study did not report whether any patients stopped taking tirzepatide because of side effects or whether they were taking other treatments at the same time [1].
Metreleptin remains the only licensed lipodystrophy-specific treatment [1]. Tirzepatide, sold as Mounjaro and Zepbound, is not approved for partial lipodystrophy [1]. It is not known from the study whether tirzepatide works better or worse than metreleptin for this condition [1].
Partial lipodystrophy is a rare fat-storage disorder [1]. The study looked at patients with several genetic subtypes, but it did not compare outcomes between subtypes [1]. The long-term effects of tirzepatide in partial lipodystrophy have not been reported [1]. It is also not known whether the weight loss was primarily fat or lean tissue, nor how many patients had diabetes or high triglycerides at the start [1].
Why it matters for patients
For people with partial lipodystrophy, treatment options are limited. Metreleptin is the only licensed treatment specific to lipodystrophy, and it may not be suitable or available for everyone [1]. The study suggests that tirzepatide might help with weight and some metabolic markers, but the evidence is not definitive because of the study design [1].
Tirzepatide is not approved for partial lipodystrophy, and the study does not prove it works for this condition [1]. It is also not known whether tirzepatide improves quality of life or reduces the risk of long-term complications in people with partial lipodystrophy [1].
What happens next
No randomized controlled trials of tirzepatide in partial lipodystrophy have been reported [1]. It is not yet known whether such trials are planned [1]. The study authors did not disclose next steps in the available information [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.